40 results on '"Baumeister, Hans"'
Search Results
2. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
3. Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.
4. Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.
5. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line
6. A two-dimensional map and database of soluble nuclear proteins from HepG2 cells as reference for identification of nutrient-regulated transcription factors
7. Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry
8. Dual Regulation Of Somatostatin Receptor Subtype 1 Gene Expression By Pit-1 In Anterior Pituitary GH3 Cells
9. The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.
10. CetuGEX and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): PK/PD results from the phase II RESGEX study.
11. GlycoExpress: a novel expression system for the optimal glycosylation of biotherapeutics: Hans Baumeister and Steffen Goletz of Glycotope describe the use of the company's GlycoExpress glycosylation platform
12. Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs
13. Glyco-optimized trastuzumab-GEX, a novel anti-HER2 monoclonal antibody with ADCC activity: A phase I clinical study in patients with HER2-positive tumors.
14. First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.
15. A Novel Human Expression System for Generating Glycoprotein with Higher Activity, Fully Human Glycosolation, and Optimized Sialylation
16. Method for the Immunological Detection of Silver-Stained Proteins on Nitrocellulose Membranes
17. Gene regulation of somatostatin receptors in rats
18. The POU Domain Transcription Factor Tst-1 Activates Somatostatin Receptor 1 Gene Expression in Pancreatic β-Cells
19. Identification of NFI-binding sites and cloning of NFI-cDNAs suggest a regulatory role for NFI transcription factors in olfactory neuron gene expression
20. Cloning, Expression, Pharmacology and Tissue Distribution of the Mouse Somatostatin Receptor Subtype 5
21. Synthesis, Storage, and Release of Vascular Endothelial Growth Factor/Vascular Permeability Factor (VEGF/VPF) by Human Mast Cells: Implications for the Biological Significance of VEGF206
22. A somatostatin receptor 1 selective ligand inhibits Ca2+ currents in rat insulinoma 1046-38 cells
23. Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. [Erratum to document cited in CA117(23):226953j]
24. The rat insulin-degrading enzyme
25. Classification of mouse liver proteins by immobilized metal affinity chromatography and two‐dimensional electrophoresis
26. Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry
27. Molecular characterization of a novel rat protein structurally related to poly(A) binding proteins and the 70K protein of the U1 small nuclear ribonucleoprotein particle (snRNP)
28. Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme
29. A somatostatin receptor 1 selective ligand inhibits Ca2+currents in rat insulinoma 1046‐38 cells
30. A somatostatin receptor 1 selective ligand inhibits Ca 2+currents in rat insulinoma 1046-38 cells
31. Schweizerische Auslandskolonisation von Staats wegen?
32. Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
33. Use of human cells of myeloid leukaemia origin for expression of antibodies
34. Tumour cell lines and uses thereof
35. Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
36. TUMOUR CELL LINES NM-F9 (DSM ACC2606) AND NM-D4 (DSM ACC2605), USES THEREOF
37. TUMOUR CELL LINES NM-F9 (DSM ACC2606) AND NM-D4 (DSM ACC2605), USES THREREOF
38. FULLY HUMAN HIGH YIELD PRODUCTION SYSTEM FOR IMPROVED ANTIBODIES AND PROTEINS
39. Book Reviews.
40. A somatostatin receptor 1 selective ligand inhibits Ca 2+ currents in rat insulinoma 1046-38 cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.